Ling Rui Pharmaceutical announced its 2023 annual report and 2024 quarterly report on April 26. In 2023, the company achieved operating income of 3.311 billion yuan, an increase of 10.31% over the previous year; net profit attributable to shareholders of listed companies was 568 million yuan, an increase of 22.09% over the previous year. The company's sales expenses and management expenses in 2023 both increased slightly compared to the same period last year, and R&D expenses fell 12.32% year on year.
羚锐制药：一季度经营性现金流净额同比下滑44.91%
Ling Rui Pharmaceutical: Net operating cash flow fell 44.91% year-on-year in the first quarter
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.